Literature DB >> 22659561

Left ventricular pressure, contractility and dP/dt(max) in nonclinical drug safety assessment studies.

R Dustan Sarazan1, John P Kroehle, Bradley W Main.   

Abstract

Increasing or decreasing cardiac contractility is an undesirable property of drugs being developed for noncardiovascular indications. The International Conference on Harmonization (ICH) Topic S7A and S7B guidelines only require the assessment of heart rate, blood pressure and the electrocardiogram in nonclinical in vivo safety pharmacology studies. Assessment of drug effects on contractility is only suggested as an optional follow-up study. However, these nonclinical safety assessment studies can detect these effects if properly designed and conducted using appropriate instrumentation. Left ventricular dP/dt is the first derivative of left ventricular pressure, which is computed by software algorithms by using calculus. Its peak value, dP/dt(max), is a common, robust and sensitive indicator of changes in cardiac contractility if experimental parameters such as preload, afterload and heart rate are well controlled. In order to ensure accuracy and avoid errors in the measurement of contractility in experimental animals, the frequency response of the pressure sensing system and the sample rate of the data acquisition system must be optimized for the signal. For dogs, nonhuman primates, and normotensive rats, all important information in a left ventricular pressure signal can be captured with a system with a frequency response of 100 Hz. Although systems with much higher frequency response can be used to measure left ventricular pressure, the output of these devices must be filtered to allow no frequencies to be acquired that are higher than one-half the sample rate of the acquisition system. Stated conversely, the sample rate of the acquisition system must be at least 2× the highest frequency contained in the signal. Failure to follow these principals can lead to incorrect results due to measurement artifacts from high frequency noise, which could be present but not detectable by the investigator. This manuscript has been written for biologists who do not have advanced knowledge of physics and/or engineering and is therefore less technical and more simplified than what would be found in the engineering literature.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22659561     DOI: 10.1016/j.vascn.2012.05.009

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  4 in total

1.  Overexpression myocardial inducible nitric oxide synthase exacerbates cardiac dysfunction and beta-adrenergic desensitization in experimental hypothyroidism.

Authors:  Qun Shao; Heng-Jie Cheng; Michael F Callahan; Dalane W Kitzman; Wei-Min Li; Che Ping Cheng
Journal:  Int J Cardiol       Date:  2015-11-06       Impact factor: 4.164

2.  Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates.

Authors:  Sebastian Polak; Michael K Pugsley; Norman Stockbridge; Christine Garnett; Barbara Wiśniowska
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

3.  Cardiac peroxisome proliferator-activated receptor δ (PPARδ) as a new target for increased contractility without altering heart rate.

Authors:  Zhih-Cherng Chen; Kung Shing Lee; Li-Jen Chen; Lin-Yu Wang; Ho-Shan Niu; Juei-Tang Cheng
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.752

4.  Effects of progranulin on the pathological conditions in experimental myocardial infarction model.

Authors:  Takahiro Sasaki; Masamitsu Shimazawa; Hiromitsu Kanamori; Yoshihisa Yamada; Anri Nishinaka; Yoshiki Kuse; Genjiro Suzuki; Tomomi Masuda; Shinsuke Nakamura; Masato Hosokawa; Shinya Minatoguchi; Hideaki Hara
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.